Trial Profile
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Pegsitacianine (Primary)
- Indications Breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors OncoNano Medicine
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 Planned End Date changed from 1 Nov 2021 to 1 Dec 2021.
- 14 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 19 Nov 2021.